DCVMN members rose to the occasion to respond to the COVID-19 pandemic as quickly and effectively as possible. Over 11.2 billion COVID-19 vaccines were produced globally in 2021 of which approximately 60% came from DCVMN member companies. In one year, 7 DCVMN members partnered with multinational companies to manufacture and supply of COVID-19 vaccines. 6 COVID-19 vaccines from DCVMN members have been granted Emergency Use Authorization (EUA) by the respective countries and WHO issued Emergency Use Listing (EUL) to 5 COVID-19 vaccines from DCVMN members.
The pandemic exposed deep inequities that have existed for years and had the hardest impact on the poorest countries, communities, and those already disadvantaged. Inequitable access to COVID-19 vaccines further highlighted the disparity between the Global North and Global South. Nevertheless, in 2021, the industry joined vaccine efforts which resulted in the largest immunization campaign in human history. After just one year since the first COVID-19 vaccine was administered, vaccine makers including biotechnology firms, developing and developed country manufacturers say voluntary collaboration to share innovation has been a key enabler for manufacturing output to reach 11.2 billion doses supplied by December 2021. (PIE CHART IMAGE)
60% of these doses came from DCVMN member manufacturers. In one year:
- 7 DCVMN members partnered with multinational companies to manufacture and supply of COVID-19 vaccines
- 6 COVID-19 vaccines from DCVMN members have been granted Emergency Use Authorization (EUA) by respective countries
- WHO had listed 5 COVID-19 vaccines from DCVMN member companies for Emergency Use Listing (EUL)
- 4 member manufacturers signed agreements in 2021with Gavi for immediate COVID-19 vaccines supply to COVAX
- On February 25th 2021, the 1st COVID-19 vaccine that reached Ghana was supplied by a DCVMN member to accelerate equitable access to COVID-19 vaccines in low-income countries
